KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Return on Sales (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Return on Sales for 10 consecutive years, with 0.1% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 17.0% year-over-year to 0.1%, compared with a TTM value of 0.09% through Dec 2025, up 21.0%, and an annual FY2025 reading of 0.08%, up 20.0% over the prior year.
  • Return on Sales was 0.1% for Q4 2025 at Teva Pharmaceutical Industries, down from 0.14% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.14% in Q3 2025 and bottomed at 0.34% in Q4 2022.
  • Average Return on Sales over 5 years is 0.04%, with a median of 0.01% recorded in 2021.
  • The sharpest move saw Return on Sales surged 120bps in 2021, then plummeted -31bps in 2022.
  • Year by year, Return on Sales stood at 0.04% in 2021, then tumbled by -833bps to 0.34% in 2022, then soared by 128bps to 0.1% in 2023, then plummeted by -167bps to 0.07% in 2024, then skyrocketed by 253bps to 0.1% in 2025.
  • Business Quant data shows Return on Sales for TEVA at 0.1% in Q4 2025, 0.14% in Q3 2025, and 0.05% in Q2 2025.